OBJECTIVE To determine the proportion of patients with lower extremity peripheral arterial
disease (PAD) who reach recommended low-density lipoprotein cholesterol (LDL-C) levels …

BACKGROUND: Patients with peripheral arterial disease (PAD) have increased mortality
compared with patients without PAD. Coronary artery disease (CAD) accounts for almost …

Background Low-density lipoprotein cholesterol (LDL-C) is associated with heightened risk
of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in …

Peripheral arterial disease (PAD) is a common disorder usually associated with silent or
symptomatic arterial disease elsewhere in the circulation and a “cluster” of cardiovascular …

Highlights•Peripheral artery disease (PAD) is characterized by increased cardiovascular
risk.•Statins remain the first-line lipid-lowering therapy to treat PAD patients.•Statins …

Background: Recent studies using ATP III guidelines show that peripheral artery disease
(PAD) patients have less optimal lipid control compared to those with coronary artery …

Effective methods to educate physicians and patients on best medical management are
needed. Further research is needed to examine the benefit of LDL-c lowering and other lipid …

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis and is
associated with high mortality due to cardiovascular events. As lipid-lowering therapy has …

Peripheral arterial disease (PAD), similar to coronary artery disease (CAD), is a significant
predictor of cardiovascular morbidity and mortality. Guidelines recommend a low-density …

Background Underutilization of proven therapies in peripheral artery disease (PAD) persists.
Implementation science may improve this, but few randomized trials exist. We conducted a …